BridgeBio Pharma

NASDAQ: BBIO ↗$72.01 USD~$5B (NASDAQ) MCAP

#Genetic Diseases (Achondroplasia, ADH1)#Cardiomyopathy (ATTR-CM)#Oncology (FGFR-driven cancers)#Rare Disease

BridgeBio Pharma is a clinical-stage biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company's pipeline includes infigratinib (FGFR-driven cholangiocarcinoma and other indications), acoramidis (ATTR-CM, approved 2024), and an achondroplasia therapy that has shown compelling growth and body-proportionality benefit in clinical data.

Company Info

Sector:Biotechnology / Genetic Disease

Headquarters:Palo Alto, California, USA

Founded:2015

Website:bridgebio.com/

Upcoming Milestones & Key Dates

Q3 2026

Earnings

Q2 2026 earnings and pipeline update

H2 2026

Clinical Trial

Achondroplasia therapy clinical updates and regulatory planning

Clinical Development Pipeline

Acoramidis (Attruby)

Target: TTR stabilizer (kinetic stabilizer)

Transthyretin amyloid cardiomyopathy (ATTR-CM)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infigratinib (Truseltiq)

Target: FGFR1-3 tyrosine kinase inhibitor

FGFR2-driven cholangiocarcinoma; additional FGFR-driven tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Achondroplasia oral therapy (infigratinib-class or successor)

Target: FGFR3 pathway modulation

Achondroplasia (pediatric growth and body proportionality)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Neil Kumar

Chief Executive Officer

Brian Stephenson

Chief Financial Officer

Dr. Jonathan Fox

Chief Medical Officer (Cardiometabolic)

Careers & Job Openings

See all open roles

Multiple Departments

Palo Alto, CA / Remote

Apply Now →